Skip to content
Evigrade
CriticalClass Ic antiarrhythmic with beta-blocking activity×HIV protease inhibitor / pharmacokinetic booster

Updated · Methodology

Mechanism

Ritonavir strongly inhibits the liver enzymes CYP3A and CYP2D6, so taken with propafenone it raises propafenone blood levels and the risk of arrhythmias and other serious propafenone adverse reactions (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). The liver turns propafenone into two active metabolites: one is formed by CYP2D6, the other by CYP3A4 and CYP1A2 (propafenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The propafenone label names ritonavir both as a CYP2D6 inhibitor and as a CYP3A4 inhibitor. Blocking both pathways at once is hazardous: propafenone builds up, and the risk of proarrhythmia and of excessive beta-blocking effects rises (propafenone label, US Food and Drug Administration, FDA). Both drugs prolong the PR interval: ritonavir in some patients, propafenone in a dose-related way together with QRS widening (ritonavir and propafenone labels, FDA).

Symptoms

Propafenone most often causes dizziness, cardiac conduction disorders and palpitations (propafenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With too much propafenone, the electrocardiogram (ECG) shows a longer PQ interval and a wider QRS complex. The sinus node slows, and atrioventricular block, ventricular tachycardia and ventricular fibrillation appear. Weaker heart contraction lowers blood pressure, in severe cases down to shock (propafenone SmPC, AEMPS). Headache, blurred vision, tingling, tremor, nausea, constipation and dry mouth also occur. Severe poisoning brings seizures, drowsiness, coma and respiratory arrest (propafenone SmPC, AEMPS). Rare second- and third-degree atrioventricular block has been reported with ritonavir in patients with heart disease, conduction abnormalities or other drugs that prolong the PR interval (ritonavir SmPC, European Medicines Agency, EMA).

Management

The combination is contraindicated. Propafenone is on the ritonavir contraindication list with no dose condition, unlike rifabutin and voriconazole. The contraindication therefore covers both treatment of human immunodeficiency virus (HIV) infection and low-dose ritonavir used to boost another protease inhibitor (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and ritonavir label, US Food and Drug Administration, FDA). The propafenone SmPC also lists ritonavir among its contraindications (propafenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Propafenone is contraindicated with the 5-day course of nirmatrelvir plus ritonavir 100 mg every 12 hours as well (Paxlovid SmPC, EMA). When ritonavir boosts another protease inhibitor, also check the contraindications in that drug's prescribing information (ritonavir SmPC, EMA, and FDA label). Review the full medicine list before starting ritonavir and before adding any new drug for a patient who already takes ritonavir (ritonavir FDA label). Even without ritonavir, record an electrocardiogram (ECG) before and during propafenone treatment (propafenone SmPC, AEMPS). If the QRS complex widens, the corrected QT interval lengthens or second- or third-degree atrioventricular block appears, lower the dose or stop propafenone until the ECG returns to normal (propafenone SmPC, AEMPS). In propafenone overdose, monitor and support vital functions in an intensive care unit. Haemodialysis does not help (propafenone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Propafenone

Other interactions with Ritonavir